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Abstract
Modification of hydrophilic proteins with amphiphilic block copolymers capable of crossing cell
membranes is a new strategy to improve protein delivery to the brain. Leptin, a candidate for the
treatment of epidemic obesity, has failed in part because of impairment in its transport across the
blood–brain barrier (BBB) that develops with obesity. We posit that modification of leptin with
poly(ethylene oxide)-b-poly(propylene oxide)-b-poly (ethylene oxide), Pluronic P85 (P85) might
permit this protein to penetrate the BBB independently of its transporter, thereby overcoming
peripheral leptin resistance. Here we report that peripherally administered leptin–P85 conjugates
exhibit biological activity by reducing food intake in mouse models of obesity (ob/ob, and diet-
induced obese mouse). We further generated two new leptin–P85 conjugates: one, Lep(ss)–
P85(L), containing one P85 chain and another, Lep(ss)–P85(H), containing multiple P85 chains.
We report data on their purification, analytical characterization, peripheral and brain
pharmacokinetics (PK). Lep(ss)–P85(L) crosses the BBB using the leptin transporter, and exhibits
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improved peripheral PK along with increased accumulation in the brain compared to unmodified
leptin. Lep(ss)–P85(H) also has improved peripheral PK but in a striking difference to the first
conjugate penetrates the BBB independently of the leptin transporter via a non-saturable
mechanism. The results demonstrate that leptin analogs can be developed through chemical
modification of the native leptin with P85 to overcome leptin resistance at the level of the BBB,
thus improving the potential for the treatment of obesity.
Keywords
Leptin; Pluronic block copolymer; Protein–polymer conjugation; Brain pharmacokinetics; Blood–
brain barrier; Obesity
1. Introduction
Leptin is a 16 kDa regulatory protein secreted by fat cells and acting within the brain to
control appetite and thermogenesis [1–3]. It crosses the blood–brain barrier (BBB) by a
specific, saturable transport system [4]. A decade ago, recombinant leptin was tested
unsuccessfully as a therapy for reduction of body weight in obese patients. We now
appreciate that the early attempts of leptin monotherapy failed because of leptin resistance
manifested in the obese patients. Animal and human studies show that leptin resistance can
occur at three levels: reduced transport at the BBB, impaired leptin receptor function in the
hypothalamus, and altered response of anorectic/orexigenic downstream neuronal circuitries
[5–7]. A great deal of effort has been made to address leptin receptor resistance. For
example, a combination of amylin with leptin led to profoundly synergistic reductions in
food intake and body weight in the obese patients and diet-induced obese (DIO) mice [8,9].
By activating amylin receptor within the hindbrain area postrema and subsequent
polysynaptic connection to the hypothalamus, amylin sensitizes the ventromedial
hypothalamus, resulting in the augmentation of leptin-induced phosphorylated signal
transducer and activator of transcription (STAT) 3 activation [8]. Leptin resistance at the
level of the BBB has also been demonstrated. Indeed, an impaired BBB transport is
important in the maintenance and probably in the progression of obesity [7,10–12]. In
particular, leptin transporter defects predominate over brain receptor defects early on in
outbred models of rodent DIO [7]. Modeling based on cerebrospinal fluid (CSF) and serum
levels of leptin indicates that in advanced obesity in humans (leptin levels of about 40 ng/
mL), transporter defects account for about 2/3 of resistance to peripheral leptin [13]. Thus,
just as in the rodent and canine models [10,14, 15], it is expected that moderately obese
humans with poor response to peripherally administered leptin [16] would still respond
better to a leptin that could reach brain receptors.
Several strategies have been explored to improve leptin action by way of peripheral
administration route. Modification of leptin with polyethylene glycol (PEG) extended leptin
serum circulation [17]. However, subcutaneous administration of PEGylated leptin failed in
clinical trials as a weight control drug for obesity treatment [18,19]. It is known that
PEGylation of proteins sometimes increases and sometimes decreases the permeability of
those proteins at the BBB [20–22], but in a specific study a PEGylated leptin was
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completely unable to cross the BBB [23]. Similarly, a genetically engineered Fc–leptin
fusion protein had no anti-obesity effect on DIO mice, although it increased serum half-life
of leptin and induced more weight loss than leptin in ob/ob mice [24]. To target brain, leptin
was also modified with trans-activating transcriptional activator (TAT), a cell-penetrating
peptide that is widely explored to facilitate cellular uptake of various molecular cargos.
After intravenous (i.v.) injection, the modified leptin was detected in a greater amount than
leptin in brain hypothalamus and showed greater response than leptin in inducing weight
loss in high-fat diet Balb/c mice [25,26]. The most recent attempt in leptin development is a
leptin peptide mimics that carries a carbohydrate moiety aiming for active transport across
the BBB. Following multiple daily intraperitoneal (i.p.) (0.5 mg/kg/day for 11 days) or
intranasal (0.1 mg/kg/day for 10 days) injections, this leptin peptide controlled body weight
gain in DIO mice [27]. The transport rate at the BBB is a key factor underlying the ability of
any substance to enter the brain and efforts have been made to improve leptin transporter
activity at the BBB. For example, leptin co-administration with epinephrine showed a
greater uptake by mouse brain [28]. Altogether, these studies suggest that overcoming
transporter resistance at the BBB and increasing delivery of leptin to the brain could
significantly improve leptin therapeutic efficacy and increase weight loss. Among the
aforementioned delivery strategies, some (e.g. leptin peptide mimics) might move to clinical
tests, while others (e.g. TAT modification) might encounter safety concerns. However, the
problem remains unresolved. Thus developing a safe, efficacious and translatable approach
to overcome peripheral resistance to leptin could address an unmet medical need and result
in a therapeutic product for the treatment of obesity.
Toward this goal we proposed to modify leptin with pluronic block co-polymers, aiming to
improve the peripheral pharmacokinetics (PK) of leptin and its brain uptake. “Pluronics” or
“poloxamers” are amphiphilic triblock copolymes consisting of (poly(ethylene oxide)-b-
poly (propylene oxide)-b-poly(ethylene oxide) (PEO–PPO–PEO, same as poly(polyethylene
glycol)-b-poly(propylene glycol)-b-poly(polyethylene glycol) or PEG–PPG–PEG). We
reported on the first generation of the modified product, Lep(ss)–P85, showing an elongated
serum half-life time, higher stability in blood and brain, and rapid transport rate across the
BBB in a non-saturable and leptin transporter independent manner [29]. The in vivo
biological activity of this Lep(ss)–P85 was shown by an acute reduction in food intake in
normal body weight mice [29]. In an extension of this approach, we have continuously
produced leptin–pluronic conjugates with the goal to improve their purity, PK profile, and
efficacy. Herein, we report the new data obtained during this optimization process that
involved conjugate production, analytical characterization, peripheral and brain PK analysis
and efficacy evaluation in models of obese mice.
2. Materials and methods
2.1. Materials
Mouse recombinant leptin (Lep) and a chimera leptin receptor (ObRFc) were purchased
from R&D Systems (Minneapolis, MN). 4-Methoxyltrityl chloride (MTr-Cl), 1,1′-
carbonyldiimidazole (CDI), 1,2-ethylenediamine (EDA), ninhydrin, L-glutathione (reduced),
ethylenediaminetetraacetic acid (EDTA), sinapinic acid, trichloroacetic acid (TCA),
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trifluoroacetic acid (TFA), iodoacetamide (IAA), triethylamine, anhydrous acetonitrile,
anhydrous pyridine, methanol, dichloromethane, toluene, acetone, ethanol, isopropanol,
dimethylformamide (DMF), PEG-SOD1 (S9549), human male AB serum and silica gel
(288616, 70– 270 mesh, 60 Å) were purchased from Sigma-Aldrich Co. (St-Louis, MO).
Pluronic P85 (P85) (lot no. WPOP-587A, average M.W. 4600) was kindly provided by
BASF Corp. (Parispany, NJ). Dithiobis(succinimidyl propionate) (DSP), disuccinimidyl
propionate (DSS), dithiothreitol (DTT) and bovine serum albumin (BSA) were from Thermo
Fisher Scientific (Rockford, IL). Carboxymethyl dextran chip (CM5), N-
hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC),
ethanolamine-HCl, HBS-EP buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005%
surfactant P20, pH 7.4), protein G, Sephadex LH-20 gel and Illustra NAP-10 or 25 columns
were from GE Healthcare (Piscataway, NJ). Amicon Ultra 0.5 mL centrifugal filters (10 kDa
MWCO) and Amicon Ultra centrifugal filter units Ultra-15 (MWCO 10 kDa) were from
Sigma-Aldrich Co. (St-Louis, MO). FLOAT-A-LYZER G2 (8–10 kDa MWCO) was from
Spectrum Laboratories, Inc. (Rancho Dominguez, CA). Flexible thin-layer chromatography
(TLC) plates were from Whatman Ltd (Mobile, AL).
2.2. Synthesis, purification and analysis
2.2.1. Synthesis of leptin–P85 conjugates—The synthesis was carried out as
previously reported [30]. Briefly, P85 was reacted with MTr-Cl (1:1 molar ratio) and
purified on Silicagel column (3 × 40 cm) with stepwise elution in dichloromethane
containing 2%, 5% and 10% methanol. The resulting mono-MTr-P85 (80% wt. yield) was
activated by excess of CDI, mixed with EDA and finally treated with TFA to remove MTr
protection. The resulting monoamine P85 was further purified using gel-permeation
chromatography on Sephadex LH-20 column (2.5 × 30 cm) in methanol. The amino groups
were assayed qualitatively by TLC and quantitatively by ninhydrin assay. To produce
leptin–P85 conjugates, the obtained monoamine P85 was activated by excess of DSP linker
followed by elution in Illustra NAP-25 columns in 20% aqueous ethanol to remove excess
of unreacted linker. Fractions containing activated P85 copolymers were immediately mixed
with leptin (molar ratio of leptin to P85 1:10) in 20% aqueous ethanol supplemented with
sodium borate buffer (0.1 M, pH 8.0). After incubation overnight at 4 °C, the reaction
mixture was precipitated in cold acetone to remove excess of free P85 copolymers, as
described previously [30]. The obtained precipitates were then desalted, sterilized and stored
for animal feeding study or further purified as described below.
2.2.2. Purification of leptin–P85 conjugates—The above obtained conjugates
(Lep(ss)–P85) were subjected to size exclusion chromatography (SEC) on TSKgel
G2000SW column (7.8 mm × 30 cm, Tosoh Bioscience LLC, Grove City, OH) using a
Shimadzu HPLC system with a multiple-wavelength UV-detector (Shimadzu Scientific
Instruments, Columbia, MD) and eluted in 0.1 M Na3PO4/0.2 M NaCl (pH 7.4) containing
10% methanol at a flow rate of 1 mL/min. Protein fractions were collected, desalted using
Amicon Ultra centrifuge filter unit and analyzed by electrophoresis and mass spectra.
Fractions eluted at 8.8 min (designated as Lep(ss)–P85(H)) and 9.5 min (designated as
Lep(ss)–P85(L)) were further sterilized and stored for animal pharmacokinetic study.
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2.2.3. MALDI-TOF spectra—Mass values of leptin–P85 conjugates were determined by
matrix-assisted laser desorption/ionization time of fly (MALDI-TOF) spectroscopy in 4800
MALDI TOF/TOF™ analyzer (Applied Biosystems/MDS SCIEX) at a laser power of 3000
V and in a positive reflector mode. Solution containing saturated sinapinic acid in 50%
acetonitrile with 0.1% TFA was used as matrix for sample preparation. Briefly, 0.5 μL of
sinapinic acid solution was coated on the plate followed by 1) depositing 0.5 μL solution of
salt free leptin–pluronic conjugates in water (10−4 M), and, 2) coating with 0.5 μL sinapinic
acid solution. The mass spectrometer was calibrated against insulin (5729.61 Da) and
albumin (66429.09 Da) (Sigma-Aldrich Co. St-Louis, MO).
2.2.4. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
—Leptin and leptin–P85 conjugates were prepared in 5 μL deionized water at a protein
concentration of 2 μg/μL (as determined by MicroBCA) and diluted (1:1) with non-reducing
denaturing loading buffer (3.8 mL of H2O, 5 mL of 0.5 M Tris–HCl (pH 6.8), 8 mL 15%
wt/vol SDS, 4 mL of glycerol, 0.4 mL of bromophenol blue 1% wt/vol). The samples were
heated for 5 min at 100 °C and then loaded to 15% precast polyacrylamide Tris–HCl gel
(Bio-Rad Life Science Research, Hercules, CA). After running for 3 hr at 120 V, the gel was
fixed in 50% methanol/10% acetic acid, stained in SYPRO® Ruby solution and scanned on
a Typhoon gel scanner.
2.2.5. Size measurements—Particle size and size distribution were measured by
dynamic light-scattering (DLS) using Zetasizer Nano-ZS instrument (Malvern, UK). Leptin
samples were prepared at 100 μg/mL concentration in deionized water, sterilized by 0.22 μm
of sterile Ultrafree-MC centrifugal filter units and kept at equilibrium at 20 °C for 5 min
prior to measurement. The particle parameters were measured for 15 min at 25 °C with a 90°
scattering angle. Mean effective hydrodynamic diameter (Deff) and volume-average size
distribution were obtained by automatically repeating (six times) the measurement based on
the Zetasizer internal setting.
2.2.6. Circular dichroism (CD) spectra—Secondary structure of leptin samples was
determined by CD spectra in Chirascan™-Plus automated CD (ACD) spectrometer (Applied
Photophyscs Ltd, UK) using a 10 mm QS Hellma cuvette. Leptin samples were dissolved in
sodium phosphate buffer (10 mM, pH 7.5) at a concentration of 0.1 mg/mL. The far UV
spectra (190–260 nm) were recorded at 25 °C with bandwidth of 1.0 nm, step of 0.5 nm and
time-per-point of 1.25 sec (50,000 repeats per point). The results were reported as mean
residual molar ellipticity ([θ] in degree · cm 2 · dmol−1) and calculated using Eq. (1)
(1)
where θ (degree) is the observed ellipticity, M (g/mol) is the molecular weight of leptin of
16.14 kDa, C (mg/mL) is the sample concentration at 0.1 mg/mL, l (cm) is the optical path
of 0.1 cm and n is the number of leptin residues of 147. The secondary structure of leptin
samples, in particular the percentage of α-helix, β-strands, β-turns and remaining structures
were determined by computer program CONTIN based on a set of standard CD spectra from
37 proteins reported in literature [31,32].
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2.2.7. LC/MSMS Orbitrap mass spectrometry—The Lep(ss)–P85 or Lep(ss)–P85(L)
was mixed with DTT (10 mM in phosphate buffer saline (PBS)) at 65 °C for 5 min followed
by IAA (10 mM) treatment at 30 °C for 30 min to block free thiol groups. This removed the
bulk of the P85 molecule but left a remnant (–C(O)CH2-CH2SCH2C(O)NH2) attached to the
Lys residues and/or N-terminus at the site of P85-modification. Samples were filtered
through Amicon Ultra centrifuge membrane to remove low molecular mass agents, and
precipitated in cold acetone to remove detached P85. Complete detachment of P85 (except
the remnant) was verified by SDS-PAGE. The precipitate was digested with trypsin using
Filter Aided Sample Preparation (FASP) protocol [33]. The peptide (2 μg of protein digest/
analysis) was loaded onto a microcapillary fused silica precolumn (2 cm × 100 μm i.d.) and
washed with 95% solvent A (0.1% formic acid in water)/5% solvent B (0.1% formic acid in
acetonitrile) for 20 min at a flow rate of 2 μL/min, using a Nano-Acquity HPLC system
(Milford, MA Waters Corp.). The pre-column was connected to a C18 analytical column (14
cm × 75 μm i.d., 5 μm particle size) and the flow rate was reduced to 250 nL/min. Peptides
were eluted by increasing solvent B to 40% over a 2 hr gradient. The effluent from the LC
system was electrosprayed directly into an LTQ Orbitrap Velos ion trap mass spectrometer
(Thermo Electron Corp.). Data were collected in a data-dependent manner with each cycle
consisting of one high-resolution mass spectrum (over a 400–2000 mass to charge (m/z)
ratio) taken from initial scan in Orbitrap and ten MSMS fragmentation spectra in LTQ ion
trap that were automatically selected from the most abundant ions in subsequent collision-
activated dissociation. The Spectra were searched by MASCOT (V 2.3 from Matrix
Science) using Proteome Discoverer program (v 1.3 from Thermo Scientific). The searching
parameters included a mass tolerance of 10 ppm, fragment ion tolerance of 0.8 Da, variable
modifications for methionine oxidation, and remnant (–C(O)CH2CH2SCH2C(O)NH2)
modification of lysine/ methionine. Peptide assignments were made based on 2 MS/MS
spectra with a Mascot Expectation value of less than 0.01 and at least one was validated
manually.
2.2.8. Enzyme-linked immunosorbent assay (ELISA)—The ELISA protocol was
kindly provided by Academia Sinica (Taipei, Taiwan). Briefly, 96-well microplates
(eBioscience, Inc. San Diego, CA) were coated first for 4 hr at 37 °C and then overnight at 4
°C with 50 μL/well of 5 μg/mL of anti-PEG antibody (AGP4, mouse IgM anti-PEG,
Academia Sinica, Taipei, Taiwan) in 35 mM NaHCO3/15 mM Na2CO3 (pH 9.3), then
blocked with 5% skim milk in PBS for 2 hr, and washed thrice with PBS. The analyzed
samples in 50 μL dilution buffer (2% skim milk in PBS) were added to each well and
incubated for 2 hr at 25 °C. Plates were washed (thrice with 0.05% Tween 20 in PBS (PBS-
T) and twice with PBS) and supplemented with 50 μL/well biotinylated anti-PEG antibody
(3.3-biotin, 5 μg/mL in dilution buffer, Academia Sinica, Taipei, Taiwan). After 1 hr at 25
°C the plates were washed and stained for 1 hr with 50 μL/well of streptavidin–HRP (1
μg/mL, Jackson ImmunoResearch Lab., West Grove, PA). Finally, the plates were washed
again and peroxidase activity was measured by adding 100 μL/well tetramethylbenzidine
(Thermo Fisher Scientific., Rockford, IL) for 5–30 min followed by 100 μL/well of stopping
reagent (Thermo Fisher Scientific, Rockford, IL). Absorbance (450 nm) was measured in
microplate reader SpectraMax M5 (Molecular devices, Sunnyvale, CA).
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2.2.9. Stability of disulfide bond in leptin–P85 conjugates—The disulfide bond
stability was investigated in the presence of human serum, mimicking extracellular
conditions, or cytosolic concentration of L-glutathione (reduced), a main contributor of
intracellular reductive environment as described in the literature [34–36]. Briefly, leptin or
Lep(ss)–P85 (100 μg) was mixed with 200 μL of sterile-filtered human male AB serum at 37
°C. Two microliters of aliquot was sampled from the mixture at desired time point, stored at
−80 °C and analyzed by standard Western blot using antibody against mouse leptin. The
aliquot samples were prepared and electrophoresed as described previously using non-
reducing denaturing loading buffer. Western blot was conducted by transferring the non-
stained gels to PVDF membrane in Tris/glycine transfer buffer (Bio-Rad) containing 20%
methanol at 60 V for 2 hr, washing thrice in Tris buffered saline (TBS) containing 0.05%
Tween 20 (TBST) and subsequent 1 hr of blocking in 5% skim milk in TBST at room
temperature (RT). To detect the blot, the membrane was probed with anti-leptin polyclonal
antibody (AF498, goat IgG anti-mouse leptin, R&D Systems, Minneapolis, MN) in TBST
containing 1% BSA overnight at 4 °C. After washing in TBST 3 times, the membrane was
incubated with donkey anti-goat IgG-HRP (1:10,000, Santa Cruz biotechnology, Inc. Dallas,
TX) at RT for 1 hr, washed thrice in TBST and twice in TBS, and then visualized using ECL
detection kit (Thermo Fisher Scientific, Rockford, IL). Densitometry analysis was conducted
using Image J (v1.47, NIH, USA) and data were presented from three independent Western
blot experiments.
To study the stability of disulfide linker upon L-glutathione (reduced) treatment, Lep(ss)–P85
or Lep(cc)–P85 (a control sample prepared using a non-degradable linker DSS, 50 μg in 500
μL PBS, pH 7.4) were dialyzed in FLOAT-A-LYZER (8–10 kDa) against PBS containing
20% ethanol and 6 mM L-glutathione (reduced) at 4 °C for 24 hr with three complete buffer
changes. Samples were then purified using Amicon Ultra 0.5 mL centrifugal filters to
remove excess of reducing re-agent. Protein content was measured using reducing agent
compatible BCA Protein Assay (Thermo Fisher Scientific, Rockford, IL). Samples were also
analyzed by mass spectra and SDS-PAGE to confirm the disul-fide bond reduction and
stored at −20 °C for further measurement of CD spectra and binding affinity.
2.2.10. Surface plasmon resonance (SPR)—The binding affinity of leptin–P85
conjugates was measured by SPR in Biacore3000 instrument (GE Healthcare, Piscataway,
NJ), using a method reported previously for leptin [37]. To prepare the sensor chip, protein
G was immobilized on CM5 (Channel A and B) by consequent injection of 1) 115 μL
NHS/EDC (1:1, vol/vol) (to activate dextran surface); 2) 60 μL protein G (200 μg/mL, 10
mM sodium acetate buffer, pH 4.0) (to bind the surface at 2000-3000 resonance units (RU)),
and 3) 75 μL of 1 M ethanolamine hydrochloride, pH 8.5 (to deactivate NHS-ester and
remove electrostatically bound protein). The Fc fragment of ObR-Fc was used to reversibly
bind to protein G that was pre-immobilized onto the sensor chip. The ObR-Fc N-terminus
represented the extracellular domain of the putative leptin transporter at the BBB (ObRa)
that interacts with circulating leptin; it also shared the sequence of leptin receptor (ObRb)
expressed in the brain for leptin binding and signal activation. Therefore, the ObR-Fc N-
terminus was adsorbed onto the sensor chip to detect leptin sample for binding affinity
measurement which could reflect leptin activity at both of the BBB level and its central
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receptor site. CM5 surface response was recorded by first, immobilization of ObR-Fc (0.5
μg/mL, 15 μL in HBS-EP, 5 μL/min flow rate) in channel A following 1800 s washing (to
capture 100–300 RU of ObR-Fc); second, capture of leptin or leptin–P85 conjugates (0–300
nM, 100 μL in HBS-EP, flow rate 20 μL/min) and dissociation (900 s) in channel A (ObR-
Fc surface) and B (protein G surface); third, regeneration of a fully active protein G surface
by 5 μL glycine (10 mM, pH 2.0). The data (sensorgrams in channel A) were corrected by
non-specific protein G surface binding (sensorgrams in channel B) and baseline drift
(sensorgrams of HBS-EP injection in channel A) which can occur due to a slow dissociation
of ObR-Fc and protein G and then fitted to a 1:1 binding model using BIA evaluation
software 3. The rate constants ka and kd were derived from these association and dissociation
data using nonlinear least square (χ2) analysis model and further used to calculate the
equilibrium dissociation constants (KD). The values shown represent average of three
separate measurements.
2.2.11. Cell proliferation assay—The proliferation assay was conducted in BaF/3 cells
transfected with the long form of human leptin receptor (hObR). Cells were cultured in
RPMI-1640 medium containing 10% fetal bovine serum, 50 μM 2-mercaptoethanol, 20
ng/mL rhleptin and 0.5 mg/mL of geneticin. To conduct proliferation assay, the cells were
harvested, washed and re-suspend at 2 × 105 cells/mL in 50 μL/well of RPMI-1640 medium
in a 96-well plate. Leptin or leptin–P85 conjugates were diluted in the same medium at
various concentrations from 0 to 50 μg/mL and added to the plate in duplicate at 50 μL/well.
The plate was incubated at 37 °C for 3 days and during the final 16–20 hr of incubation
period, 10 μL/well of a 0.1 mg/mL resazurin was added. Cell proliferation was assessed by
measuring the fluorescent intensity at the excitation wavelength of 544 nm and at emission
wavelength of 590 nm. The data were analyzed using a 4-parameter fit and the activity was
interpreted as IC50.
2.3. Feeding study
The feeding study was conducted in St. Louis University School of Medicine using
procedures that are approved by the National Institutes of Health Guide for Care and Use of
Laboratory Animals. Male ob/ob mice, 8 weeks of age, were purchased from Jackson
laboratories (Bar Harbor, MA). Male CD-1 from in house colony was placed into two
groups at 3 weeks of age. This mouse has been used by us and others in DIO models [38].
To produce DIO mice, one group was placed on regular chow (5001 rodent diet, PMI
Nutritional International, Brentwood, MO; 4.5% fat) and one group was placed on breeder
chow (Teklad mouse breeder diet, Harlan-Teklad, Madison, WI; 10% fat) for 4 months. At
the end of this time, total body weights were 40.4 ± 2.81 (mean ± SD) in regular chow mice
(estimated 10 g of body fat 30) and 58.1 ± 6.3 g (estimated 30 g of body fat) in breeder
chow mice. Mice were individually housed prior to the start of the food intake studies.
Ob/ob mice were weighted. Mice were then given a subcutaneous (s.c.) injection of either
Lep(ss)–P85 (40 μg/day) or vehicle. On days 2 and 3 mice food and body weights were
taken and mice were given s.c. injection of the same dose of Lep(ss)–P85 or vehicle. On day
4 food and body weights were taken. This design is similar to our previous study in ob/ob
mice [38]. In the study using DIO mice, mice were food deprived overnight. In one group of
mice intracerebroventricular (i.c.v.) surgery was applied using the procedure described
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previously [29]. Prior to drug treatment, mice were lightly anesthetized with isoflurane, and
an injection of Lept(ss)–P85 (25 μg) or vehicle was given i.c.v. In another group, mice
received an i.v. injection of Lep(ss)–P85 (3 mg) or vehicle via tail vein. For both groups 15
min. post injection a known amount of food was placed in the cage. Two and 24 hr later the
food was weighted to determine 2 hr and 24 hr intake.
2.4. PK studies
2.4.1. Radioactive labeling—Leptin or leptin–P85 conjugates were radioactively labeled
by chloramine-T method as previously described for Lep(ss)–P85 [29]. Briefly, 5 μg of
leptin or 10 μg of leptin analogs was mixed with 1 mCi Na131I or 0.5 mCi Na125I
(PerkinElmer Life Sciences, Boston, MA), respectively, in a final volume of 45 μL sodium
phosphate buffer (0.25 M, pH 7.5). A freshly made 10 μg of chloramine-T solution (2 μg/μL,
in 5 μL sodium phosphate buffer) was added to the mixture; after 60 s incubation with
mixing, the radioactively labeled substance was purified with Illustra NAP-5 columns (GE
Healthcare, Piscataway, NJ). Fractions were collected in Eppendorf tubes pretreated with
1% BSA in lactated Ringer's solution (1% BSA-LR) to prevent non-specific absorbance and
counted in a PerkinElmer γ-counter. Similarly, albumin was labeled by Na131I using
chloramine-T method and purified with Illustra NAP-5 columns. TCA precipitation was
conducted to determine the iodine association of labeled samples. Briefly, 1 μL of collected
fractions was added to 0.5 mL of 1% BSA-LR and then precipitated in 0.5 mL of 30% TCA
followed by centrifuging at 5400 g for 10 min at 4 °C. The resulting supernatant and pellet
were counted in a γ-counter and the values used to calculate the percent of radioactivity that
was precipitated with acid. Samples containing N100,000 cpm/μL of radioactivity and
N90% precipitation from TCA were used for the animal studies.
2.4.2. Animal procedures—The PK experiments were conducted in CD-1 male mice (8
to 10 weeks of age) (Charles River Laboratories, Wilmington, Mass) in the Department of
Medicine, University of Washington under an approved IACUC protocol. The mice had free
access to food and water and were maintained on a 12-hr dark/light cycle in a room with
controlled temperature (24 ± 1 °C) and humidity (55% ± 5%). Mice were anesthetized with
an i.p. injection of 0.2 mL of urethane (4.0 g/kg). Radioactively labeled substances were i.v.
injected into the jugular vein in a volume of 0.2 mL of 1% BSA-LR. Blood from the pre-
exposed right carotid artery was collected at various time points after injection; mice were
immediately decapitated and then the whole brain was removed and weighed. In some cases,
a procedure that washed out the vascular contents of the brain was performed before
decapitation. In these animals, the arterial blood was collected from the abdominal aorta in
an open abdomen prior to wash out. After the collection of the arterial blood, the thorax was
opened, the descending thoracic was clamped, both jugular veins were severed, the heart
was exposed, and 1% BSALR was perfused into the left ventricle of the heart over 1 min.
Finally, the mouse was decapitated and the whole brain removed and weighed.
2.4.3. Serum clearance, influx rate and brain vascular volume—Mice were given
an i.v. injection of 300,000 cpm of 125I-Lep(ss)–P85(L) or 125I-Lep(ss)–P85(H) co-injected
with 300,000 cpm of 131ILep. Blood and brain samples were collected between 2 and 90
min after i.v. injection. In a separate study, mice were given an i.v. injection of 300,000 cpm
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of an 125I-leptin analogs with 300,000 cpm of 131I-albumin (131I-Alb); brain and serum were
collected between 2 and 180 min after injection. The arterial blood was centrifuged at 5400g
for 10 min at 4 °C, and the serum was collected. The levels of radioactivity in serum (50 μL)
and brain samples were counted in the dual channel γ-counter. At the end of the experiment,
the radioactivity of the material from the injection vial was counted and used to determine
the amount of material administered. For samples containing both of 125I and 131I
radioactivity, radioactivity levels were measured in the dual channel γ-counter capable of
distinguishing between the two isotopes. To calculate the clearance from serum, the level of
radioactivity was expressed relative to the amount injected (%Inj/mL) and these values were
plotted against time (min) to obtain the serum concentration vs time curve. The brain/serum
ratios for 131I-leptin or for 125I-leptin analogs were expressed in units of μL/g of brain. In
some cases, the brain/ serum ratio for 125I-leptin analogs was corrected for the vascular
space by subtracting the brain/serum ratio of the co-injected 131I-Alb in each individual
mouse. These brain/serum ratios were then plotted against exposure time and multiple-time
regression analysis used to calculate the blood-to-brain unidirectional influx rate (Ki) and
volume of distribution for brain (Vi), using Eq. (2) [39,40].
(2)
where the brain/serum ratio (Am/Cpt) is calculated by cpm/g of brain (Am) normalized by
cpm per microliter of arterial serum at time t (Cpt); the exposure time (0tCp(t)dt/Cp(t)) was
calculated as the area under the serum concentration time curve divided by the serum
concentration at time t.
The slope for the linear portion of the relation between the brain/ serum ratios and respective
exposure times is Ki, measured in units of μL/g · min and representing the rate at which
compounds are moving across the BBB from the circulation into the brain parenchyma; The
y-intercept of the line represents Vi, the apparent volume of material that is distributed to the
brain parenchyma at time 0, measured in μL/g of tissue weight.
2.4.4. Stability of serum and brain samples—Mice were given i.v. injection of
300,000 cpm of an 125I-leptin analog that also contained 300,000 cpm of 131I-leptin. Arterial
blood and brain were collected at 15, 60 and 240 min after injection and the stability was
determined by TCA precipitation. In a separate group, mice were given an i.v. injection
containing 1,000,000 cpm of an 125I-leptin analog and 1,000,000 cpm of 131I-leptin. Prior to
brain and serum collection, a brain washout was performed as described previously at 240
min following administration. The blood sample was processed as described previously and
the resulting serum (50 μL) was precipitated in 0.5 mL of 1%BSA-LR with 0.5 mL of 30%
TCA followed by centrifugation. The brain sample was homogenized in 3 mL of sodium
phosphate buffer (0.25 M, pH 7.5) for 10 strokes, and then centrifuged at 5400g for 10 min
at 4 °C. The obtained brain supernatant was then precipitated in an equal volume of 30%
TCA followed by centrifugation. To correct for the degradation of radioactivity during the
ex-vivo processing, serum or brain from untreated animals was directly exposed to
radioactively labeled samples and then processed identically as above. The radioactivity in
acidified serum and brain supernatants and pellets as well as the processing controls were
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counted in a γ-counter. The stability of serum and brain samples was accessed by the percent
of radioactivity precipitated in the pellet and normalized by the values for processing
controls.
2.4.5. Brain uptake—Mice received an i.v. injection of 125I-Lep(ss)–P85(L) or 125I-
Lep(ss)–P85(H) with a co-injection of 131I-leptin as described in Section 2.4.3. Brain
samples were collected 240 min after injection from animals without brain washout. Brain
uptake was calculated using Eq. (3) to obtain the percent of the injected dose entering each
gram of brain tissue (%Inj/g). These values were further corrected for the sample stability
assessed based on acid precipitation.
(3)
2.4.6. Inhibition study—To determine the role of the BBB transporter in the BBB
penetration of the leptin analogs, 10 μg/mouse of nonradioactive recombinant leptin was co-
injected with 125I-Lep(ss)–P85(L) and 131I-leptin or 125ILep(ss)–P85(H) and 131I-leptin in
the 0.2 mL of 1% BSA-LR into the jugular vein of CD-1 mice. Blood and brain samples
were collected 30 min after i.v. injection and processed as described previously. Samples
were counted in a dual channel γ-counter. Brain to serum ratio was calculated for each
isotope in each group (n = 10/group).
2.4.7. Statistical analysis—Statistical analysis was done using Student's t-test for two
groups and one-way ANOVA followed by Newman–Keuls multiple comparison test. A
minimum p value of 0.05 was estimated as the significance level. Statistic analysis was done
with the Prism 5.0 software (GraphPad, San Diego, CA, USA).
3. Results
3.1. Effect of leptin–P85 conjugates on feeding in obese mice
Leptin–P85 conjugates in this work were produced by modifying leptin primary amino
groups (Lys residues and N-terminal) with NHS-activated mono-amine P85 using disulfide-
containing linker (Scheme 1). The conjugate obtained using this chemistry, Lep(ss)–P85 was
reported previously [29]. This conjugate as discussed below contains several modified forms
of leptin along with unmodified leptin. It was shown to maintain biological activity in
reducing food intake of normal CD1 mice at a dose of 4 μg per mouse following i.c.v.
injection or at a dose of 3 mg per mouse following tail vein injection. To further confirm the
biological effect of this conjugate in obese mice, here we reported the acute food intake
response of Lep(ss)–P85 in ob/ob mice and DIO mice. After 3 days of treatment, s.c.
injection of Lep(ss)–P85 at dose of 40 μg per mouse induced significant weight loss (p <
0.006) and a decrease of food intake (p < 0.02) in ob/ob mice (n = 6 ~ 7/group) (Fig. 1).
Direct administration of Lep(ss)–P85 at 25 μg per mouse into the lateral ventricle of the
brain in DIO mice drastically reduced food intake, a 18% decrease over the next 24 hr (n =
5/group, p < 0.03), comparing to that in the control group that received the vehicle injection
(Fig. 2A). The reduced food intake was also observed in DIO mice 2 hr (p < 0.001) and 24
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hr (p < 0.0001) after tail vein injection of Lep(ss)–P85 at a dose of 3 mg per mouse (n = 10/
group) (Fig. 2B and C).
3.2. Purification and characterization of leptin–pluronic conjugates
3.2.1. Fractionation and analysis of conjugates by HPLC—In spite of
demonstrated biological activity and previously reported improvements in brain PK profile,
the initial Lep(ss)–P85 conjugate was a fairly heterogeneous product that contained
unmodified leptin and leptin modified with 1 or more P85 chains. To improve its purity and
homogeneity, a fractionation method by SEC was established to remove the majority of
unmodified leptin and isolate leptin modified with 1 P85 chain and multiple P85 chains (Fig.
3A). In SDS-PAGE (Fig. 3B) the fraction eluted at 8.8 min (Lep(ss)–P858.8 min) displayed a
major MW band (indicated by arrow in Lane C), corresponding to leptin modified with 2
P85 chains and a smear above the band, representing leptin modified with 3 or more P85
chains. The major band corresponding to fraction eluted at 9.5 min (Lep(ss)–P859.5 min) was
leptin modified with 1 P85 chain (indicated by arrow in Lane D). Characterization of these
fractions by mass spectra further confirmed that HPLC SEC was able to reduce the
heterogeneity, resulting in Lep(ss)–P859.5 min containing mainly 1 P85 chain (mass peak
detected at 21 kDa) and Lep(ss)– P858.8 min containing mainly 2 and 3 P85 chains (mass
peak detected at 26 and 31 kDa) (Fig. 3C). Therefore, Lep(ss)–P859.5 min and Lep(ss)–
P858.8 min were further designated as Lep(ss)–P85(L) and Lep(ss)–P85(H), respectively.
The elution profile (Fig. 3A) was generally similar to that previously observed during
fractionation of pluronic-modified superoxide dismutase (SOD1) using the TSKgel
G3000SW SEC column [41]. While both methods were adopted from purification of SOD1-
PEG (PEG at 5 kDa) [42], the elution resolution for these P85 modified proteins was notably
lower than that for SOD1-PEG, most likely due to the effect of the hydro-phobic PPO block
of pluronic. To tackle the problem, we attempted to purify Lep(ss)–P85 using hydrophobic
interaction chromatography (HIC). After optimization of elution conditions, we were able to
isolate leptin attached with 1 P85 chain (Lep(ss)–P85(L)) from unmodified leptin but the
elution of the more hydrophobic species, Lep(ss)– P85(H), did not succeed (Supplementary
data Fig. S1).
3.2.2. Particle size and protein secondary structure—The DLS measurements of
the particle size for the 100 μg/mL of native leptin, Lep(ss)–P85, Lep(ss)–P85(L) and
Lep(ss)–P85(H) in distilled water resulted in the Deff values of 3.8 ± 0.2 nm (PDI 0.27), 15
± 1 nm (PDI 0.43), 10.4 ± 3.5 nm (PDI 0.60) and 8.4 ± 0.4 nm (PDI 0.68) respectively. The
increased size and PDI indices observed for the conjugate samples, were probably, due to
self-assembly of Pluronic-modified protein in an aqueous solution.
The secondary structures of leptin and Lep(ss)–P85 conjugates were analyzed using CD
spectra (Fig. 4A). Consistent with the literature, recombinant mouse leptin exhibited high
content of α-helix (67%) featured by negative bands at 208 and 222 nm, no β-sheet and 8%
of β-turn [43]. The CD spectrum of Lep(ss)–P85 (un-fractionated mixture) was generally
similar to that of leptin suggesting presence of 49% α-helix, 20% β-turn and absence of β-
sheet. Overall the CD data indicated the proper protein folding. However, changes in signal
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intensity, a decrease in α-helix and an increase in β-sheet content in Lep(ss)–P85 suggest
that leptin has undergone some conformation changes in the course of the modification.
3.2.3. Identification of modification sites in leptin–P85 conjugates—Mouse
recombinant leptin contains eight primary amino groups (seven Lys residues and the N-
terminus), which all could be modified (Supplementary data Fig. S2). The site(s) of
modification was determined by LC/MSMS Orbitrap mass spectrometry. Of the eight
primary amino groups, five modification sites (Lys 6, 12, 16, 34 and 107) were identified in
both of Lep(ss)–P85 and Lep(ss)–P85(L) conjugates (Fig. S2).
3.2.4. Immunoassays of leptin–P85 conjugates using Anti-PEG antibody—To
confirm the presence of P85 in leptin conjugates, a double sand wich ELISA was performed
using the monoclonal anti-PEG backbone antibody AGP4 and 3.3-biotin. Previously these
antibodies were successfully used to assay PEGylated proteins and nanoparticles [44–49]. In
this work using ELISA we were able to quantitatively measure PEGSOD1 (5 kDa PEG,
multiple PEG chains) and Lep(ss)–P85 at concentrations as low as ca. 0.001 μg/mL and 0.1
μg/mL respectively (Fig. 4B). In contrast, no signal was observed for free P85 and native
leptin. Moreover, this ELISA did not recognize Lep(ss)–P85(L) that contained a single P85
chain; this finding was consistent with the prior report, in which a similar ELISA assay
failed to recognize lysozyme modified with a single PEG chain of 2 kDa or 5 kDa [49].
Finally, no ELISA signal was observed for SOD1 modified with multiple pluronic L81, a
copolymer with nearly the same length of PPG but much shorter PEG block compared to
P85 (Supplementary data Fig. S3), indirectly suggesting that AGP4 antibody is selective to
PEG rather than PPG. Altogether, these results suggest that the anti-PEG antibody
recognizes P85 chains linked to leptin. However, quantitative measurement using this
antibody was only possible for leptin–P85 conjugates containing multiple P85 chains.
Moreover, in addition to the number of polymer chains linked to the polymer this assay is
dependent on the length of PEG block. The used ELISA assay relies on the ability of both
the capture and detection antibodies (AGP3 and biotin3.3) to bind with the PEG chain to
detect the PEGylated protein. Lep(ss)–P85(L) contains leptin modified with a single P85
chain, carrying approximately 2.3 kDa PEG molecule. To produce positive ELISA signal
both AGP3 and biotin3.3 would need to bind with the same fairly short PEG chain, which
most likely is sterically hindered. Similarly, the free P85, once it is captured by AGP3,
possibly cannot be detected by biotin3.3 because of the steric hindrance.
3.2.5. Disulfide bond stability in serum—To examine stability of the disulfide bond in
the presence of serum, Lep(ss)–P85 or leptin (control) was incubated with human serum (0.5
μg/μL) at 37 °C for up to 24 hr and analyzed by Western blot using anti-leptin antibody.
There was no change in the profile of native leptin showing one major band at 16 kDa
corresponding to monomeric form at either 0 or 24 hr. Lep(ss)–P85 contained multiple
species, including a monomeric and a dimer form of leptin (16 and 32 kDa), and leptin
conjugates modified by one, two and multiple P85 chains (as indicated by arrows) (Fig. 5).
Although there were some apparent changes in the density of bands, the differences
particularly for the leptin monomer were marginal (Supplementary data Fig. S4). Most
importantly, Lep(ss)–P85 conjugate at all time points displayed similar bands. These results
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suggest that Lep(ss)–P85 remains stable in serum for at least 24 hr with little if any disulfide
bond reduction and release of P85.
3.2.6. In Vitro binding of leptin–P85 conjugates to the leptin receptor—The in
vitro activity of leptin–P85 conjugates was examined by SPR and cell proliferation assays.
The SPR association and dissociation pro-files were recorded for native leptin, Lep(ss)–P85,
Lep(ss)–P85(L), and a mixture of native leptin and free P85 copolymer (Fig. 6A). The
resulting kinetic constants, ka (“on rate”) and kd (“off rate”) were used to calculate KD
(Table 1). Native leptin displayed extremely fast association and slow dissociation phases,
resulting in a KD of ca. 10−10 M. This activity was of the same order of magnitude as
previously reported value [37]. Interestingly, the binding affinity for the leptin and P85
mixture decreased 3 fold, suggesting that free P85 interferes with interaction of native leptin
with its receptor. The Lep(ss)–P85 mixture including modified leptin conjugates with
multiple P85 chains displayed a dramatic decrease in the binding affinity as exhibited by
500 fold increase in KD compared to that of the native leptin. In contrast, a more
homogenous sample Lep(ss)–P85(L) with low degree of modification displayed much
higher binding affinity, although it was still 12 fold less active than the native leptin. The in
vitro activity was further measured by a cell-based proliferation assay using in BaF/3-hObR
cells. Here the results were somewhat different. Based on this assay, IC50 of mouse
recombinant leptin was 0.08 ng/mL, consistent with the activity reported from its vendor,
R&D System. The IC50 of Lep(ss)–P85(L) and Lep(ss)–P85(H) decreased about 14 and 18
fold respectively compared to that of unmodified leptin (Fig. 6B and Table 1). Surprisingly,
Lep(ss)– P85 displayed high activity in the proliferation assay relative to activity shown in
the SPR study, with IC50 of Lep(ss)–P85 being only 5 fold less than IC50 of leptin. The
presence of unmodified leptin in the Lep(ss)– P85 mixture appears to explain relatively
higher activity shown in the proliferation assay by this mixture compared to purified
Lep(ss)– P85(L) and Lep(ss)–P85(H) forms.
3.2.7. Disulfide bond cleavage in Lep(ss)–P85 conjugates—We posit that the
disulfide bond in the Lep(ss)–P85 conjugate may be cleaved in the biological milieu.
Therefore, the disulfide bond stability was studied by exposing Lep(ss)–P85 samples to L-
glutathione (reduced), a major chemical that contributes to the reductive intracellular
environment. The disulfide bond in the Lep(ss)–P85 conjugate was considerably, albeit not
completely reduced after 24 hr incubation with L-glutathione (reduced). This was evident in
mass spectra by the disappearance of a signal for leptin modified with two P85 chains and a
decrease of a signal for leptin modified with one P85 chain (Supplementary data Fig. S5). In
comparison to the non-degradable analog, Lep(cc)–P85 did not display any change in the
mass spectra before or after treatment by L-glutathione (reduced) (Supplementary data Fig.
S5). Notably, both Lep(ss)–P85 and its reduced form, Lep(s ≠ s)-P85 exhibited almost
identical CD spectra, showing some decrease in α-helix and increase in β-sheet content
compared to native leptin (Fig. 4A). Thus, removal of the P85 chain from leptin did not
result in a recovery of the secondary structure of leptin to its native form. That could be due
to the presence residual groups, –C(O)CH2CH2SH or – C(O)CH2CH2S-glutathione, which
may remain attached to the leptin amino groups after cleavage of the P85 moiety from
Lep(ss)–P85 (Fig. S2). However, another possibility is that the leptin secondary structure
Yi et al. Page 14






















was affected during its exposure to L-glutathione (reduced), for example, as a result of thiol
exchange reaction with the unique disulfide bond of leptin (Fig. S2). In favor of this
suggestion is that the treatment of native leptin with L-glutathione (reduced) also produced a
similar CD spectrum to that of Lep(ss)–P85 (Fig. 4A). In spite of minimal changes in its
secondary structure, according to the SPR assay Lep(s ≠ s)–P85 did exhibit a higher binding
affinity as shown by 3 fold decrease in the dissociation constant KD compared to that of the
non-reduced Lep(ss)–P85 form (Table 1). Therefore after cleavage of P85 in vitro Lep(ss)–
P85 partially regained the receptor binding affinity although it never reached the level
observed for the native leptin.
3.3. PK of Lep(ss)–P85 conjugates
The brain PK profile of leptin–pluronic conjugate, Lep(ss)–P85 has been previously
reported by us [29]. In brief when compared to native leptin after i.v. injection Lep(ss)–P85
had a longer half-life in blood and similar influx rate across the BBB. Here we determined
three major components of this Lep(ss)–P85 mixture: unmodified leptin, Lep(ss)–P85(H)
and Lep(ss)–P85(L)). These components would have collectively contributed to the PK
profile in our prior study. Thus, we radioactively labeled each component and studied their
serum clearances and brain uptakes.
3.3.1. Serum clearance—To compare the PK profiles of leptin and leptin–P85
conjugates, we co-injected 131I-leptin with 125I-labeled conjugates to each animal, collected
the brain and serum samples, and measured 125I and 131I radioactivity for each sample.
Statistical comparisons of these results thus minimize the variability originating among
individual animals as two compounds are assessed in each animal. The serum clearance
curve was obtained by plotting serum radioactivity (%In/mL) vs. time (min). A first-order
kinetics was observed for the early phase of clearance of all substances, which was
demonstrated by the statistically signifi-cant relation between log(%Inj/mL) and time t (Fig.
7). Serum half-life (t1/2) of leptin, Lep(ss)–P85(L) and Lep(ss)–P85(H) was 11.98 min,
40.75 min and 75.8 min respectively, suggesting that pluronic modification prolonged leptin
circulation, with a higher number of P85 chains attached to the protein producing a longer
circulation time. The serum half-life for the unpurified conjugates, Lep(ss)–P85, was
reported previously at 32.35 min [29], consistent with that being a mixture of all three forms
of leptin. The initial vascular volume distribution for all three substances was not
significantly different from each other, indicating that the addition of pluronic moieties did
not alter distribution of leptin outside of the vasculature.
3.3.2. Influx rate across the BBB—The brain/serum ratios were plotted vs. exposure
times and analyzed by multiple-time regression (Fig. 8). In this analysis the slope of the
linear portion of the plot determined the blood-to-brain unidirectional influx rate, Ki and the
Y-intercept determined the distribution volume in brain at t = 0 (Vi). The previously
reported value of Ki of Lep(ss)–P85 mixture at the BBB was 0.272 ± 0.037 μL/g · min,
which is not statistically different from Ki of leptin [29,50]. Here, both Lep(ss)–P85(L) and
Lep(ss)–P85(H) crossed the BBB at a slower rate than the co-injected leptin (Fig. 8A and
B), as shown by their ca. 6.2 to 6.4-fold lower influx rates (KiLep(ss)–P85(L) = 0.038 ± 0.008
μL/g min vs KiLepti n = 0.236 ± 0.017 μL/g · min, KiLep(ss)–P85(H) = 0.020 ± 0.007 μL/g ·
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min vs KiLepti n = 0.129 ± 0.011 μL/g · min). The initial volume of brain distribution was
also reduced for both purified conjugates. Both Lep(ss)–P85(L) and Lep(ss)–P85(H),
however, did cross the BBB at a rate faster than albumin. This was evident from positive
values of their influx rates corrected for the vascular space using co-injected albumin (Fig.
8C and D).
3.3.3. Stability of serum and brain samples—The stability of leptin–P85 conjugates
in serum and brain was assayed using acid precipitation, a previously established method
allowing to estimate the integrity of the iodinated leptin [4]. As shown in Table 2, the
percentage of radioactivity recovered from serum and brain, as an indicator of the protein
integrity, was highest in the Lep(ss)–P85(H) group, followed by Lep(ss)–P85(L) group and
lowest in the leptin group. It is notable that this difference was negligible for samples
collected at 15 min following i.v. injection when degradation of the leptin and its analogs
was minimal. However, at the later time points as degradation of native leptin became more
pronounced the greater stability of the leptin conjugates became more evident. In addition,
Lep(ss)–P85(H) brain samples collected from mice with a brain washout were also more
stable than that of Lep(ss)–P85(L) and leptin (51% vs 34% and 17%).
3.3.4. Brain uptake—The brain uptake (%inj/g brain) was determined at 240 min
following i.v. administration of 125I-Lep(ss)–P85(H) or 125I-Lep(ss)–P85(L) with co-
injection of 131I-leptin. To obtain the uptake of intact protein in the brain parenchyma, the
%inj/g in brain was corrected for the Vi of each radioactively labeled substance. The
resulting brain uptake of Lep(ss)–P85(L) and Lep(ss)–P85(H) more likely represents the
amount of the substance that has crossed the BBB and as presented here shows that both
compounds had significantly higher brain uptakes compared to that of native leptin (Fig. 9).
3.3.5. Inhibition study—The role of the leptin transporter in the BBB penetration of the
leptin analogs was assessed by the effect of co-injection of excess of nonradio-active leptin
(10 μg/mouse) on the brain uptake of 125I labeled leptin– P85 conjugates and co-
injected 131I-leptin at 30 min following injection. As shown in Fig. 10, in the presence of
free leptin, both 125I-Lep(ss)– P85(L) and 131I-leptin showed a significant decrease in their
brain/ serum ratios (p < 0.05 for 125I-Lep(ss)–P85(L) and p < 0.005 for 131I-leptin, n = 10/
group), whereas no significant changes was observed for 125I-Lep(ss)–P85(H) (n = 10/
group). These results suggest that leptin modified by a single P85 chain crosses the BBB
using leptin transporter; however, Lep(ss)–P85(H) modified with several P85 chains enters
the brain independently of the leptin transporter.
4. Discussion
Modification of proteins with synthetic polymers has been studied for several decades.
PEGylation, the leading technology in this field, has achieved enormous success in
improving bioavailability and therapeutic efficacy of proteins for diseases with peripheral
pathological targets. Like PEGylation, modifications with amphiphilic Pluronic triblock
copolymers can decrease degradation of proteins in physiological fluids. Additionally, it
increases permeability of proteins at physiological barriers, such as the BBB. Leptin, is one
of the molecules that we have modified using this technology, aiming to improve its brain
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delivery and effects on feeding. The first generation of leptin–P85 conjugate, Lep(ss)–P85
was biologically active and reduced food intake of normal body weight mice at doses of 3
mg/mouse i.v. and 25 μg/mouse i.c.v. [29]. An extensive PK study reported for Lep(ss)–P85
showed its longer blood circulation, better stability in serum and brain, and most
importantly, transport across the BBB via a leptin transporter independent pathway [29].
This suggests that pluronic modification can potentially overcome leptin peripheral
resistance and formed the basis for the further work reported here.
The initial progress in this work was the improvement of the purification of Lep(ss)–P85 by
SEC, allowing the removal of the majority of unmodified leptin and isolation of two more
homogenous conjugates: Lep(ss)–P85(L) and Lep(ss)–P85(H). Next, we studied serum and
brain PK for these two conjugates and compared them to the native leptin. We found that 1)
both conjugates were superior to the native leptin in terms of the blood PK and 2) the higher
the modification degree of the conjugate is, the greater their blood half-life and serum
stability are (i.e. Lep(ss)–P85(H) N Lep(ss)–P85(L) N leptin). Moreover, in the brain tissue
Lep(ss)–P85(H) was also more stable than Lep(ss)–P85(L) and both conjugates were much
more stable than native leptin. Notably, both Lep(ss)–P85(H) and Lep(ss)–P85(L) entered
the brain from the blood at slower rates than that of leptin. However, despite their decreased
influx rate, both Lep(ss)–P85(L) and Lep(ss)–P85(H) accumulated in the brain in greater
amounts than leptin as assessed at 240 min after injection. The increased uptake of these
conjugates to the brain is most likely due to the improvement in their peripheral PK and the
higher stability within the brain, which compensate for some loss of their BBB permeability.
Remarkably, the transport inhibition studies demonstrated that these conjugates exploited
strikingly different pathways for the brain entry. Specifically, Lep(ss)–P85(H) was crossing
the BBB by a mechanism independent of the leptin transporter; whereas Lep(ss)–P85(L)
penetrated the BBB by a mechanism inhibited by leptin. We posit that attaching multiple
P85 chains to leptin in Lep(ss)–P85(H), could considerably diminish its interaction with the
leptin transporter at the BBB. However, hydrophobic PPG blocks could interact with lipids
membranes and as a synthetic carrier, triggering the endocytosis of Lep(ss)–P85(H) at the
brain endothelium. P85 alone, for example, is known to bind to lipid rafts and transport in
brain microvessel endothelial cells through both caveolae and caveolae- and clathrin-
independent endocytosis routes [51,52]. It is possible that similar mechanisms are also
involved in the BBB permeability of Lep(ss)–P85(H) in vivo with P85 chains attached to
leptin serving as synthetic transport elements. Lipid moieties have been purposefully
introduced to therapeutic small molecules and peptides to gain a better penetration at the
BBB via diffusion mechanism [53]. However, to date, the largest reported molecule to
diffuse across the BBB is CICN1 with molecular weight of 7.8 kDa, at least 4 time smaller
than Lep(ss)–P85(H) (N26 kDa) [54]. Therefore it is less likely that the slow and non-
saturable penetration of Lep(ss)–P85(H) involves trans-cellular diffusion at the brain
endothelium. In a striking difference Lep(ss)–P85(L) modified with a single copolymer
chain seems to cross the BBB mainly via interaction with the leptin transporter. This
suggests that on the one hand attaching a single P85 chain to leptin possibly cannot trigger
sufficient hydrophobic interaction with brain endothelium necessary to bypass the BBB
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transporter. On the other hand, modification of leptin with a single P85 chain does not
completely block the ability of the analog to bind the leptin transporter.
In parallel to the purification and brain PK profile, we characterized the physicochemical
properties of leptin–P85 conjugates by various analytical assays. Using Lep(ss)–P85 as an
example, we observed an increase in the hydrodynamic diameter of particles measured by
DLS, suggesting some aggregation of the modified protein that may be an issue for further
pharmaceutical development. We also observed some changes in the secondary structure of
the modified leptin analog, which was not rectified by chemical cleavage of the P85 chains
in a test tube. Interestingly, the binding affinity of Lep(ss)–P85 to its receptor in SPR assay
was 500 fold less than that of leptin, whereas in the cell proliferation assay it was only 5 fold
less as compared to leptin. The apparent discrepancy is not very clear and may have
something to do with differences in interaction of P85 modified protein with SPR substrate
and cell membranes. In the first case the block copolymer chains may adhere to and mask
the leptin sites responsible for binding with the receptor. This may also involve
unconjugated leptin molecules, which could incorporate into protein aggregates observed by
the DLS. In the proliferation assay studies, however, the block copolymer chains may bind
with the cell membrane thus making leptin molecules more available for interacting with
their receptors. This speculation of course would need to be confirmed in the future.
We also for the first time report here the points of the copolymer attachment to leptin in the
Lep(ss)–P85 conjugates as determined by Orbitrap mass spectrometry. These are amino
groups of Lys 6, 12, 16, 34 and 107. To visualize how each modification could affect leptin
interaction with its receptor, we determined the 3D structure of each isomer of P85 modified
leptin using molecular modeling and further aligned the structure with a reported molecular
model of putative leptin–receptor complex [55]. Attaching P85 at Lys 6 and 12 notably
causes steric hindrance for leptin interaction with its receptor. However, modification at Lys
16, 34, 107 in all likelihood provides less steric barrier for the leptin–receptor binding
(Supplementary data Fig. S6). Notably, the leptin transporter at the BBB displays structural
similarity to the leptin receptor [56]. Therefore, the results of this analysis may explain why
Lep(ss)–P85(L) modified with a single copolymer chain is still capable to transport across
the BBB via the receptor mediated route. However, the leptin analog with higher
modification degree, Lep(ss)–P85(H) seems to be less likely to enter the brain though the
transporter dependent pathway. However, these two analogs did not show much difference
in cell proliferation assay, which complicates the simple explanation and may mean that the
binding of these analogs with receptors in cell membranes is more complex than assumed in
the model.
In the design of our leptin–pluronic conjugates, we purposefully introduced the disulfide
bond, the linkage that can degrade intracellularly yet is relatively stable in plasma [34]. With
this reversible disulfide bond, Lep(ss)–P85 might act as a prodrug that presents in a
modified form during circulation, allowing for improved peripheral bioavailability, but then
releases free leptin with translocation across the BBB. Indeed, we found no disulfide
breakdown upon exposure of Lep(ss)–P85 to serum for up to 24 hr. Our most recent results
also suggest that the conjugates are fairly stable after exposure to brain homogenates.
Whether the conjugate is broken down during penetration of the BBB is yet to be
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determined. On the other hand Lep(ss)–P85 conjugate was shown to release leptin, albeit
incompletely, when treated with L-glutathione, an agent, which at least partially recaptures
the reductive intracellular environment. This suggests the possibility that leptin might be
released from its prodrug Lep(ss)–P85 within brain endothelium.
Finally we tested the anti-obese effect of leptin–P85 conjugates in two models of obese
mice. The ideal and most interesting compound in this regard would be Lep(ss)–P85(H),
considering its lower heterogeneity, improved PK profile, and BBB penetration independent
of the leptin transporter. However the current conjugation chemistry and post purification
procedure limit the supply of a large quantity of Lep(ss)–P85(H) for feeding studies. As we
think the rationale of modification is to overcome peripheral resistance, which was shown
by both Lep(ss)–P85(H) and Lep(ss)–P85, the latter compound, which at this stage is easier
and more affordable to produce in needed amounts, was tested here. The first model was the
ob/ob mouse that produces no leptin and is very sensitive to its effects. It was used here to
determine whether the conjugated leptin retained any biological activity. We found that a
rather modest dose of 40 μg/ mouse given by the s.c. route decreased both feeding and body
weight. This showed that the mixture form of leptin–pluronic conjugate, Lep(ss)–P85 can be
produced that retains leptin-like activity. It is very likely that all three components of
Lep(ss)–P85, Lep(ss)– P85(L), Lep(ss)–P85(H) and native leptin can contribute to this
activity because each component can be transported across the BBB of ob/ob mice. The
second model we tested was the DIO mouse, which demonstrates both central and especially
peripheral resistance to leptin. We found that Lep(ss)–P85 was active after i.c.v. injection,
demonstrating its activity once it reaches leptin receptors at the arcuate nucleus. We then
determined whether i.v. injected Lep(ss)–P85 could inhibit feeding. This would require
leptin to cross the BBB in the animal model that is characterized by peripheral resistance to
leptin. We found that tail vein injection evoked an acute response in reduction of food intake
at a dose of 3 mg/mouse. In contrast to ob/ob mice, DIO mice most likely cannot respond to
Lep(ss)– P85(L) and native leptin forms because of insufficient transport of these forms to
the brain. At the same time, Lep(ss)–P85(H) penetrates to the brain and thus contributes to
the food reduction effect observed in DIO mice. While the ultimate goal is to prove its
improvement in treating DIO, we are currently exploring the dose response curve of leptin
substance and hope to address this key question based on an appropriate dose comparison
between leptin and the conjugates in either acute or/and long term feeding experiment.
5. Conclusion
In this study we generated two new leptin–pluronic conjugates. Lep(ss)–P85(H), a leptin
analog containing multiple P85 chains and Lep(ss)–P85(L), a leptin analog containing one
P85 chain. Lep(ss)– P85(H) is a promising anti-obesity drug candidate because of its
improvement in peripheral bioavailability, its increased brain uptake and, most importantly,
its ability to cross the BBB independently of the leptin transporter. Lep(ss)–P85(L) also
shows promise to be developed as leptin therapy alternative because of improved PK and
brain bioavailability.
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Generation of leptin–P85 conjugates by modifying leptin lysine and N-terminal amino
groups with monoamine P85 via disulfide-containing linker. The leptin–P85 conjugate
Lep(ss)–P85 was further purified to produce Lep(ss)–P85(L) and Lep(ss)–P85(H).
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The effect of peripherally administered Lep(ss)–P85 in ob/ob mouse. (A) Body weight in
ob/ob mice after 3 days of Lep(ss)–P85 treatment (40 μg/day/mouse, s.c.) was significantly
decreased (p < 0.006, by t-test). (B) Lep(ss)–P85 treatment also induced a significant
reduction in average daily food intake (p < 0.02, by t-test) (n = 6 for vehicle group and n = 7
for Lep(ss)–P85 group).
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The effects of Lep(ss)–P85 in DIO mice. (A) The DIO mice that received 25 μg/mouse i.c.v.
Lep(ss)–P85 ate significantly less food 24 hr post food induction than mice that was given
with vehicle. (n = 5/group, p < 0.03, by t-test). (B and C) Tail vein injection of Lep(ss)–P85
at a dose of 3 mg per mouse significantly reduced food intake of DIO mice 2 hr (p < 0.001)
and 24 hr (p < 0.0001) post food induction (n = 10/group).
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Purification and characterization of leptin–P85 conjugates. (A) Lep(ss)–P85 conjugate
contained unmodified leptin and leptin modified with different numbers of P85 chains. SEC
elution profile in TSKgel G2000SW column showed separation of leptin–P85 conjugates
from unmodified leptin. (B) SDS-PAGE and (C) MALDI-TOF spectra further characterized
the collected fractions at 8.8 min and 9.5 min as leptin conjugates modified with multiple
P85 chains (Lep(ss)–P85(H)) and single P85 chain (Lep(ss)–P85(L)), respectively.
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(A) CD spectra of native leptin and Lep(ss)–P85 before and after reduction of disul-fide
bonds with 6 mM reduced L-glutathione. (B) Immunoassays of leptin–pluronic conjugates
using antibody against PEG. Concentration-dependent ELISA signal was present in Lep(ss)–
P85, but not in free P85, native leptin or Lep(ss)–P85(L). A PEGylated protein (PEG-SOD1)
was also assayed as a positive control showing that AGP 4 and 3.3-biotin antibody were able
to recognize PEG containing species.
Yi et al. Page 28























Disulfide bond stability in Lep(ss)–P85 conjugate upon its exposure to serum. Western blot
analysis shows that leptin or Lep(ss)–P85 remained stable after incubating with serum for up
to 24 hr.
Yi et al. Page 29























(A) Representative association and dissociation SPR sensorgrams of leptin–pluronic
conjugate at various concentrations flowing on the sensor chip coupled by leptin receptor.
(B) Binding curves of leptin–pluronic conjugates with BaF3 mouse pro-B cells transfected
with human leptin receptor.
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Serum clearance of leptin–pluronic conjugates during shorter (A and B) and longer time
periods of study (C and D). The two lines in panels A and B were significantly different (p <
0.05). Both 125I-Lep(ss)–P85(L) and 125I-Lep(ss)–P85(H) showed significantly longer
circulation time than that of co-injected 131I-leptin. The serum disappearance (T1/2) was
40.75 min for 125I-Lep(ss)–P85(L) (r = 0.75, p < 0.001; n = 1 ~ 2 mice/time point), 75.80
min for 125I-Lep(ss)–P85(H) (r = 0.73, p < 0.0005; n = 1 ~ 2 mice/time point) and 11.98 min
for 131I-Lep (r = 0.64, p p < 0.005; n = 1 ~ 2 mice/time point). The vascular volume
distribution (Vi), as shown by the y intercept was not significantly different. Panels C and D
further showed that initial serum clearance was a linear distribution for both of leptin
analogs followed by a plateau phase.
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Multiple-time regression analysis of leptin–pluronic conjugate transport across the BBB.
Leptin–P85 conjugates were labeled by 125I and co-injected with 131I-lep (A and B)
or 131IAlb (C and D). (A and B) The two lines in each figure were statistically different (p <
0.0001). Both Lep(ss)–P85(L) and Lep(ss)–P85(H) showed a slower entry rate compared to
that that of leptin. The brain volume distribution (Vi), however, was not significantly
different. The Ki for Lep(ss)–P85(L) and Lep(ss)–P85(H) was 0.038 ± 0.008 μL/g · min (r =
0.71, p < 0.0.005; n = 1 ~ 2 mice/time point) and 0.020 ± 0.007 μL/g · min (r = 0.40, p <
0.05; n = 1 ~ 2 mice/time point), respectively. The Vi for Lep(ss)–P85(L) and Lep(ss)–
P85(H) was 16.62 ± 0.94 μL/g and 14.70 ± 1.48 μL/g, respectively. For native leptin co-
injected with Lep(ss)–P85(L), the Ki was 0.236 ± 0.017 μL/g · min and Vi was 17.17 ± 1.19
μL/g (r = 0.96, p < 0.0001); for leptin co-injected with Lep(ss)–P85(H), the Ki was 0.129 ±
0.011 μL/g · min and Vi was 16.16 ± 1.49 μL/g (r = 0.94, p < 0.0001). Both leptin results
were similar to those reported previously. (C and D) Results were corrected for vascular
space as measured by 131I-Alb. Both leptin analogs showed residual uptake rates after this
correction, suggesting that they had significantly higher entry rates than that of albumin. The
Ki for Lep(ss)–P85(L) was 0.011 ± 0.003 μL/g · min; the Vi was 3.034 ± 0.298 μL/g (r =
0.45, p < 0.01; n = 1 ~ 2 mice/time point). The corrected Ki for Lep(ss)–P85(H) was 0.018 ±
0.004 μL/g · min; Vi was 3.391 ± 0.35 μL/g (r = 0.48, p < 0.001; n = 1 ~ 2 mice/time point).
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Brain uptake of intact leptin analogs at 240 min after i.v. injection. The brain uptake of 125I-
Lep(ss)–P85(L) or 125I-Lep(ss)–P85(H) was significantly higher than that of co-
injected 131I-Lep (*p < 0.05, n = 2 ~ 3/group, by t-test). The brain uptake was expressed as
%inj/g using Eq. (3) and then corrected for the stability of the brain samples (in washout
brain) as assessed by TCA precipitation.
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Transport mechanisms of leptin analogs. (A) Nonradioactive leptin (10 μg/mouse) inhibited
the brain/serum ratio of both 125I-Lep(ss)–P85(L) and 131I-Lep at 30 min after intravenous
injections (*p < 0.05; **p < 0.001, n = 10/group), suggesting a transporter dependent
mechanism across the BBB. (B) The brain/serum ratio of 125I-Lep(ss)–P85(H) at 30 min
after intravenous injections did not alter with or without excess of leptin (10 μg/ mouse) (*p
< 0.05, n = 10/group).
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Table 1





kD [10–10 M] χ 2 IC50 [ng/mL] R 2
Leptin 1.0 ± 0.03 0.1–0.4 0.08 0.99
Leptin + P85 3.37 ± 0.08 0.3–0.5 ND ND
Lep(ss)–P85 571 ± 91.50 0.2–0.6 0.448 0.99
Lep(s ≠ s)–P85 164 ± 15.50 0.2–0.3 ND ND
Lep(ss)–P85(H) ND ND 1.472 0.99
Lep(ss)–P85(L) 12.1 ± 5.14 0.8–1.5 1.102 0.99
a
Binding affinity was measured by SPR in Biacore 3000 and analyzed in BIA evaluation software 3 using χ2 analysis. The lower χ2, the better the
fitting is.
b
IC50 was measured by CPA using BaF3 mouse pro-B cells transfected with human leptin receptor and calculated by four parameter fitting with
R2 of 0.99 for all curves.
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Table 2
Acid precipitation of radioactively labeled leptin or its analogs in brain and serum.
Time (min) Leptin Lep(ss)–P85(L) Lep(ss)–P85(H)
Serum (%) Brain (%) Serum (%) Brain (%) Serum (%) Brain (%)
15 94.4 ± 3.6 100.0 ± 3.9 104.0 ± 0.7 99.1 ± 1.6 100.3 ± 6.5 98.8 ± 5.6
60 76.2 ± 8.5 73.0 ± 13.7 93.3 ± 1.1 73.9 ± 1.6 96.1 ± 0.4 81.9 ± 0.4
240 52.8 ± 8.7 27.7 ± 9.5 71.0 ± 2.7 49.7 ± 3.3 86.0 ± 3.4 61.5 ± 3.3
240
a 35.7 ± 10.9 17.6 ± 16.1 74.0 ± 1.1 34.3 ± 3.3 87.0 ± 1.01 51.2 ± 8.2
a
Brain was collected in mice with a brain washout.
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